Auris Medical Holding AG (NASDAQ:EARS) – Equities researchers at Leerink Swann issued their Q3 2016 earnings per share estimates for Auris Medical Holding AG in a note issued to investors on Tuesday. Leerink Swann analyst J. Schwartz anticipates that the brokerage will earn ($0.29) per share for the quarter. Leerink Swann also issued estimates for Auris Medical Holding AG’s Q4 2016 earnings at ($0.31) EPS, FY2016 earnings at ($1.11) EPS, FY2017 earnings at ($0.85) EPS and FY2018 earnings at ($0.95) EPS.

Earnings History and Estimates for Auris Medical Holding AG (NASDAQ:EARS)

A number of other analysts have also weighed in on the stock. Needham & Company LLC raised their target price on shares of Auris Medical Holding AG from $5.00 to $11.00 and gave the company a “buy” rating in a research report on Friday, August 19th. Zacks Investment Research lowered shares of Auris Medical Holding AG from a “buy” rating to a “hold” rating in a research report on Tuesday, August 16th. Finally, JMP Securities lowered shares of Auris Medical Holding AG from an “outperform” rating to a “market perform” rating in a research report on Thursday, August 18th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $8.88.

Shares of Auris Medical Holding AG (NASDAQ:EARS) traded down 8.51% during trading on Friday, reaching $1.29. 217,154 shares of the company were exchanged. The stock’s 50-day moving average is $1.71 and its 200-day moving average is $3.25. Auris Medical Holding AG has a 52-week low of $1.29 and a 52-week high of $7.96. The firm’s market cap is $44.28 million.

Several institutional investors have recently modified their holdings of EARS. TFS Capital LLC raised its position in shares of Auris Medical Holding AG by 17.7% in the second quarter. TFS Capital LLC now owns 38,230 shares of the company’s stock worth $160,000 after buying an additional 5,762 shares during the period. Advisor Group Inc. acquired a new position in shares of Auris Medical Holding AG during the second quarter worth approximately $277,000. Finally, Bellevue Group AG acquired a new position in shares of Auris Medical Holding AG during the first quarter worth approximately $7,897,000. Institutional investors own 30.95% of the company’s stock.

Auris Medical Holding AG Company Profile

Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration.

5 Day Chart for NASDAQ:EARS

Receive News & Stock Ratings for Auris Medical Holding AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical Holding AG and related stocks with our FREE daily email newsletter.